Vibeleaderboard

Learn from the corpus

Latest IntelNews, research, field notes, and releases reviewed by the editorial system.Agentic Engineering RoadmapLearn the field in order through lessons built from current Intel.

Glossary Knowledge graph

BrowseAll Tools Browse by capability Head-to-head Market map Model Atlas

Find the right skill, CLI, harness, or service for the job.

Popular capabilities

Code with an agentWork across a repository from an issue, prompt, or terminal session.→Interface with your agentsCLI harnesses, IDEs, control planes, desktop apps, multiplexers, and terminals for steering coding agents.→Connect tools with MCPExpose data and actions to agents through Model Context Protocol servers.→Review any codebaseGive an agent a repeatable, high-signal engineering review process.→Find AI benchmarksSWE-bench, Terminal-Bench, Harvey LAB, and more→Dictate instead of typeSuperwhisper and Wispr Flow→

Explore

AI labsLiving dossiers on the organizations behind the models.

Index — Latest Intelligence

Intel

Company

About→Contact→Submit→Developers→

Legal

Privacy→Terms→

Follow us@vibeleaderboard↗

© 2026 Vibeleaderboard

Tnik Ipf Phase2a | VibeLeaderboard

Intel / article

Tnik Ipf Phase2a

Source: Insilico Medicine News
Author: Insilico Medicine News
Date: Published Aug 3, 2026

Why it matters

A generative-AI-designed drug candidate cleared a randomized Phase IIa trial with measurable efficacy, concrete evidence that AI-driven target and molecule design can produce clinically active compounds, not just faster screening.

Read the source ↗insilico.com

Recommended reads

articleAI-designed rentosertib lowers predicted biological age across six proteomic clocksInsilico Medicine
postAn agent generated a cancer hypothesis, and the lab confirmed itAi2
article🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai DiscoveryRJ Honicky

Comments

Checking sign-in…

Loading comments…